Urogen Pharma Ltd
URGN19.830USD
+0.430+2.22%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
837.46MCap. mercado
PérdidaP/E TTM
Más Datos de Urogen Pharma Ltd Compañía
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Información de la empresa
Símbolo de cotizaciónURGN
Nombre de la empresaUrogen Pharma Ltd
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoMs. Elizabeth A. (Liz) Barrett
Número de empleados235
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 04
Dirección9 Ha'ta'asiya St
CiudadRA'ANANA
Bolsa de valoresNASDAQ Global Market Consolidated
PaísIsrael
Código postal4365007
Teléfono97297707601
Sitio Webhttps://www.urogen.com/
Símbolo de cotizaciónURGN
Fecha de salida a bolsaMay 04, 2017
Director ejecutivoMs. Elizabeth A. (Liz) Barrett
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
41.49K
+27.61%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Mr. Vincent Perrone
Mr. Vincent Perrone
Investor Relations
Investor Relations
--
--
Mr. Daniel G. Wildman
Mr. Daniel G. Wildman
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Arie S. Belldegrun, M.D.
Dr. Arie S. Belldegrun, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
408.69K
--
Ms. Elizabeth A. (Liz) Barrett
Ms. Elizabeth A. (Liz) Barrett
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
326.69K
--
Mr. Jason Drew Smith
Mr. Jason Drew Smith
Chief Compliance Officer, General Counsel, Corporate Secretary
Chief Compliance Officer, General Counsel, Corporate Secretary
41.49K
+27.61%
Mr. Christopher (Chris) Degnan
Mr. Christopher (Chris) Degnan
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer
--
--
Mr. James A. Robinson, Jr.
Mr. James A. Robinson, Jr.
Independent Director
Independent Director
--
--
Dr. Mark P. Schoenberg, M.D.
Dr. Mark P. Schoenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Por negocioUSD
Nombre
Ganancia
Proporción
Jelmyto
20.25M
0.00%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Jelmyto
20.25M
0.00%
Estadísticas de accionistas
Actualizado: dom., 27 de jul
Actualizado: dom., 27 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RTW Investments L.P.
8.30%
RA Capital Management, LP
6.94%
TD Securities, Inc.
6.91%
UBS Asset Management (Switzerland)
5.71%
Soleus Capital Management, L.P.
5.03%
Other
67.11%
Accionistas
Accionistas
Proporción
RTW Investments L.P.
8.30%
RA Capital Management, LP
6.94%
TD Securities, Inc.
6.91%
UBS Asset Management (Switzerland)
5.71%
Soleus Capital Management, L.P.
5.03%
Other
67.11%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
28.01%
Investment Advisor/Hedge Fund
23.81%
Hedge Fund
22.04%
Research Firm
10.69%
Venture Capital
10.21%
Insurance Company
6.72%
Corporation
4.78%
Bank and Trust
2.45%
Individual Investor
2.08%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
285
52.24M
113.07%
+4.72M
2025Q1
290
49.25M
108.64%
+1.67M
2024Q4
280
43.94M
103.24%
-1.94M
2024Q3
262
44.13M
104.63%
-2.19M
2024Q2
247
46.02M
111.40%
+11.07M
2024Q1
255
34.96M
99.86%
+5.57M
2023Q4
237
29.16M
94.80%
+4.33M
2023Q3
238
25.93M
86.41%
+2.69M
2023Q2
222
19.52M
83.40%
-392.05K
2023Q1
221
19.00M
81.20%
-1.17M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RTW Investments L.P.
3.83M
8.32%
--
--
Mar 31, 2025
RA Capital Management, LP
3.21M
6.95%
+3.21M
--
Mar 31, 2025
TD Securities, Inc.
2.65M
5.75%
+903.36K
+51.65%
Jun 09, 2025
UBS Asset Management (Switzerland)
2.64M
5.73%
+1.28M
+94.68%
Mar 31, 2025
Soleus Capital Management, L.P.
2.33M
5.04%
+2.33M
--
Jun 13, 2025
Menora Mivtachim Insurance Ltd.
2.30M
4.99%
--
--
Mar 31, 2025
Vestal Point Capital, LP
2.15M
4.67%
+522.96K
+32.08%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.14M
4.65%
-50.01K
-2.28%
Mar 31, 2025
UBS Asset Management (Americas) LLC
1.72M
3.73%
+1.72M
--
Mar 31, 2025
Acorn Capital Advisors, LLC
1.52M
3.29%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
ARK Israel Innovative Technology ETF
1.96%
Hypatia Women CEO ETF
1.9%
ALPS Medical Breakthroughs ETF
0.43%
iShares Micro-Cap ETF
0.11%
ProShares Ultra Nasdaq Biotechnology
0.07%
Invesco Nasdaq Biotechnology ETF
0.07%
iShares Biotechnology ETF
0.06%
iShares Russell 2000 Growth ETF
0.03%
SPDR S&P International Small Cap ETF
0.03%
Global X Russell 2000 ETF
0.02%
Ver más
ARK Israel Innovative Technology ETF
Proporción1.96%
Hypatia Women CEO ETF
Proporción1.9%
ALPS Medical Breakthroughs ETF
Proporción0.43%
iShares Micro-Cap ETF
Proporción0.11%
ProShares Ultra Nasdaq Biotechnology
Proporción0.07%
Invesco Nasdaq Biotechnology ETF
Proporción0.07%
iShares Biotechnology ETF
Proporción0.06%
iShares Russell 2000 Growth ETF
Proporción0.03%
SPDR S&P International Small Cap ETF
Proporción0.03%
Global X Russell 2000 ETF
Proporción0.02%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
